Page 75 - CIBERES2016-ENG

Most relevant scientific articles
• Milara J, Morell A, Ballester B, Armengot M, Morcillo EJ, Cortijo J. MUC4 impairs the anti- inflammatory effects of corticosteroids in chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology. 2016.
• Milara J., Escriva J., Ortiz J.L., Juan G., Artigues E., Morcillo E. et al. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: An ex vivo/in vitro study. European Respiratory Journal. 2016;47(6):1737-1749.
• Morales-Cano D, Moreno L, Barreira B, Briones AM, Pandolfi R, Moral-Sanz J et al. Activation of PPARβ/δ prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries. Clinical science (London, England : 1979). 2016;130(20):1823-36.
• Gonzalez-Sanz R., Mata M., Bermejo-Martin J., Alvarez A., Cortijo J., Melero J.A. et al. ISG15 is upregulated in respiratory syncytial virus infection and reduces virus growth through protein ISGylation. Journal of Virology. 2016;90(7):3428-3438.
• Milara J, Cervera A, de Diego A, Sanz C, Juan G, Gavaldà A et al. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients.Respiratory research. 2016;17(1):145.
Highlights
During 2016, three public funding projects have been continued. The first one, started in 2013 and whose researcher is Javier Milara, is entitled: Study of the Janus Kinasa 2 / STAT3 route as a pharmacological target in idiopathic pulmonary fibrosis and associated pulmonary hypertension: preclinical and translational analysis, financed project by Health Research Fund ISCIII. The second of them, whose investigator in charge is Julio Cortijo was initiated in 2015 and your title is: New anti-inflammatory drugs in COPD and asthma. Study in models of in vitro corticoresistencia financed by the Ministry of Economy and Competitiveness and finally the last one initiate also in 2015 and whose responsible investigator is Esteban Morcillo has as its title: Pharmacological modulation of signaling inflammation-remodeling by isoform- selective inhibitors of PDE4 and Comparators in relevant in vitro human models in COPD financed by the Ministry of Economy and Competitiveness.
On the other hand during this year also has participated in projects of private financing. The first one
was based on the differential effects of Advanced Compound with comparators; panPDE4B inhibitor, selective PDE4B inhibitor, selective PDE4D inhibitor, roflumilast N-oxide and corticosteroids on leukocyte/ endothelium interactions in in vitro models relevant to COPD financed by Grünenthal GmbH. In the second, the analysis of Mucociliary Clearance of test compounds using microCT-SPECT-Tc99m albumin nanocolloids in Guinea Pig. Project financed by Almirall. Finally, the study of effects of NOX4 inhibitors on primary fibroblasts from IPF patients; an in vitro study, a project financed by Glenmark Pharmaceuticals Limited company, is currently underway.
In addition to the projects mentioned, the group has participated in events of scientific diffusion among them in the congress of the European Respiratory Society and two doctoral theses have been presented as well as 4 end-of-degree / master’s degrees.
RES
research groups 75